Dublin, April 13, 2021 (GLOBE NEWSWIRE) -- The "Allergic Conjunctivitis Market, Global Forecast Treated Patients By Countries, Disease Type, Pipeline Drugs, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
Allergic conjunctivitis is common ophthalmic disorder caused by reactions to allergens like pollen or mold spores, dust mites and animal fur. The eyeball has a membrane called conjunctiva which is receptive towards the irritation from allergens.
In July 2020, IACTA Pharmaceuticals & Zhaoke Ophthalmology Pharmaceuticals Ltd has signed an agreement to accelerate the development of drugs called IC265 and IC 270. Earlier they were develop to treat dry eye and later for allergic conjunctivitis.
There are many types of allergic conjunctivitis such as seasonal allergic conjunctivitis is caused by airborne mold spores, spring, late summer, or early fall and disappear during the winter month & perennial allergic conjunctivitis is caused by dust, mites, animal dander, and other non-seasonal allergens.
According to this research, Allergic Conjunctivitis Market was US$ 1.5 Billion in 2020 is expected to grow with a CAGR of 8.81% and reach US$ 2.7 Billion by 2027.
There has been significant increase allergic conjunctivitis due to increase in the use of chemicals and pollution caused by urbanization, industrialization and climate change. The increase in awareness of allergic conjunctivitis is associated its medical treatment & upcoming therapies such as Zerviate, ADX-102, PRT-2761, OTX-DP etc. is one of the factors driving the market.
Many Pharmaceutical companies are trying to develop many new possibilities of treatment for allergic conjunctivitis such as Zerviate, EM-100, ADX-102, PRT-2761, and OTX-DP. For instance, EyeMax LLC's EM-100 is currently in phase 3 of clinical trial, where its effectiveness is being checked in the treatment of ocular itching. Presently, around two third of new treatment options are in phase 2 or 3 of clinical trials.
The publisher has studied by region of North America followed by Europe and Asia-Pacific. The allergic conjunctivitis treatment market in Asia Pacific is expected to grow rapidly, due to having a large population base and increased demand of improved health facilities.
Key Topics Covered:
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
5. Global Allergic Conjunctivitis Market and Patients Analysis
5.2 Patient Numbers
5.3 Treated Patient Numbers
6. Share Analysis - Global Allergic Conjunctivitis
6.1 Country Market Share
6.2 Patients Population Share
6.3 Treated Patients Population Share
6.4 By Disease Type Share
7. India - Allergic Conjunctivitis Analysis
7.1 Patient Numbers
7.2 Treated Patient Numbers
8. China - Allergic Conjunctivitis Analysis
8.1 Patient Numbers
8.2 Treated Patient Numbers
9. Japan - Allergic Conjunctivitis Analysis
9.1 Patient Numbers
9.2 Treated Patient Numbers
10. United States - Allergic Conjunctivitis Analysis
10.1 Patient Numbers
10.2 Treated Patient Numbers
11. United Kingdom - Allergic Conjunctivitis Analysis
11.1 Patient Number
11.2 Treated Patient Numbers
12. France - Allergic Conjunctivitis Analysis
12.1 Patient Numbers
12.2 Treated Patient Numbers
13. Germany - Allergic Conjunctivitis Analysis
13.1 Patient Numbers
13.2 Treated Patient Numbers
14. Italy - Allergic Conjunctivitis Analysis
14.1 Patient Numbers
14.2 Treated Patient Numbers
15. Spain - Allergic Conjunctivitis Analysis
15.1 Patient Numbers
15.2 Treated Patient Numbers
16. Disease Type - Global Allergic Conjunctivitis Market
16.1 Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC)
16.2 Vernal Keratoconjunctivitis (VKC)
16.3 Atopic Keratoconjunctivitis (AKC)
16.4 Giant Papillary Conjunctivitis (GPC)
17. Global Allergic Conjunctivitis Pipeline Drugs
17.2 OTX-DP (Dexamethasone Insert)
18. Company Analysis
18.1 Santen Pharmaceutical
18.1.1 Company Overview
18.1.2 Recent Developments
18.1.3 Financial Insight
18.2 Alcon Inc. (Novartis)
18.2.1 Company Overview
18.2.2 Recent Developments
18.2.3 Financial Insight
18.3 Portola Pharmaceuticals Inc.
18.3.1 Company Overview
18.3.2 Recent Developments
18.3.3 Financial Insight
18.4 Ocular Therapeutix Inc.
18.4.1 Company Overview
18.4.2 Recent Developments
18.4.3 Financial Insight
For more information about this report visit https://www.researchandmarkets.com/r/jphju9
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900